Modern Surgical Therapy: Limb Salvage and the Role of Amputation for Extremity Soft-Tissue Sarcomas

Surgical Oncology Clinics of North America

Volumn 21, Issue 2, 2012, Pages 201-213

  Ferrone, Marco L ^a   Raut, Chandrajit P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Extremity sarcoma; Limb infusion limb perfusion; Limb salvage; Radiation therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADJUVANT THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONTRAST ENHANCEMENT; DISTANT METASTASIS; DRUG EFFICACY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPERTHERMIA; ISOLATED LIMB INFUSION; ISOLATED LIMB PERFUSION; LEIOMYOSARCOMA; LIMB AMPUTATION; LIMB PERFUSION; LIMB SALVAGE; LIMB SPARING SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; RECURRENCE RISK; REVIEW; SOFT TISSUE SARCOMA; SURGICAL MORTALITY; TREATMENT INDICATION; VASCULAR SURGERY;

AMPUTATION; BRACHYTHERAPY; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; LIMB SALVAGE; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SALVAGE THERAPY; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 84857422629     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.11.001     Document Type: Review

References (38)

1. Lahat G., Lazar A., Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin North Am 2008, 88:451-481. v.
2. Shiu M.H., Castro E.B., Hajdu S.I., et al. Surgical treatment of 297 soft tissue sarcomas of the lower extremity. Ann Surg 1975, 182:597-602.
3. Gronchi A., Lo Vullo S., Colombo C., et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 2010, 251:506-511.
4. Weitz J., Antonescu C.R., Brennan M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003, 21:2719-2725.
5. Gutierrez J.C., Perez E.A., Moffat F.L., et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg 2007, 245:952-958.
6. Clark M.A., Fisher C., Judson I., et al. Soft-tissue sarcomas in adults. N Engl J Med 2005, 353:701-711.
7. Grimer R., Judson I., Peake D., et al. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010, 2010:506182.
8. Rosenberg S.A., Tepper J., Glatstein E., et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982, 196:305-315.
9. Yang J.C., Chang A.E., Baker A.R., et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998, 16:197-203.
10. Baldini E.H., Goldberg J., Jenner C., et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999, 17:3252-3259.
11. O'Sullivan B., Davis A.M., Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002, 359:2235-2241.
12. Davis A.M., O'Sullivan B., Turcotte R., et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005, 75:48-53.
13. Brennan M.F., Hilaris B., Shiu M.H., et al. Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy. Arch Surg 1987, 122:1289-1293.
14. Pisters P.W., Harrison L.B., Leung D.H., et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996, 14:859-868.
15. Raut C.P., Albert M. Soft tissue sarcoma brachytherapy. Brachytherapy: applications and techniques 2007, 269-310. Lippincott Williams & Wilkins, Philadelphia. P.M. Devlin (Ed.).
16. Andrews S.F., Anderson P.R., Eisenberg B.L., et al. Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2004, 59:475-480.
17. Eggermont A.M., de Wilt J.H., ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003, 4:429-437.
18. Hayes A.J., Neuhaus S.J., Clark M.A., et al. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007, 14:230-238.
19. Bonvalot S., Rimareix F., Causeret S., et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 2009, 16:3350-3357.
20. Di Filippo F., Giacomini P., Rossi C.R., et al. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo 2009, 23:363-367.
21. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996, 224:756-764. [discussion: 64-5].
22. Grunhagen D.J., de Wilt J.H., Graveland W.J., et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006, 106:1776-1784.
23. Eggermont A.M., Schraffordt Koops H., Lienard D., et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996, 14:2653-2665.
24. Verhoef C., de Wilt J.H., Grunhagen D.J., et al. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol 2007, 8:417-427.
25. Bonvalot S., Laplanche A., Lejeune F., et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?. Ann Oncol 2005, 16:1061-1068.
26. Deroose J.P., Burger J.W., van Geel A.N., et al. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?. Ann Surg Oncol 2011, 18:321-327.
27. Cherix S., Speiser M., Matter M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol 2008, 98:148-155.
28. Olieman A.F., Pras E., van Ginkel R.J., et al. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998, 40:807-814.
29. Hegazy M.A., Kotb S.Z., Sakr H., et al. Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007, 14:568-576.
30. Moncrieff M.D., Kroon H.M., Kam P.C., et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2008, 15:2749-2756.
31. Turaga K.K., Beasley G.M., Kane J.M., et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg 2011, 146:870-875.
32. Bacci G., Picci P., Gitelis S., et al. The treatment of localized Ewing's sarcoma: the experience at the Istituto Ortopedico Rizzoli in 163 cases treated with and without adjuvant chemotherapy. Cancer 1982, 49:1561-1570.
33. Alvegard T.A., Sigurdsson H., Mouridsen H., et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989, 7:1504-1513.
34. Le Cesne A., Woll P.J., Bramwell V.H., et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): pooled analysis of the two STBSG-EORTC phase III clinical trials. J Clin Oncol 2008, 26:10525.
35. Cavaliere R., Ciocatto E.C., Giovanella B.C., et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967, 20:1351-1381.
36. Lindner L.H., Issels R.D. Hyperthermia in soft tissue sarcoma. Curr Treat Options Oncol 2011, 12:12-20.
37. Issels R.D., Lindner L.H., Verweij J., et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010, 11:561-570.
38. Ghert M.A., Abudu A., Driver N., et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol 2005, 12:10-17.